Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cardiodynamic trial of Piclidenoson (CF101) in healthy volunteer

Next Previous
Trial Profile

Cardiodynamic trial of Piclidenoson (CF101) in healthy volunteer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Aug 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Piclidenoson (Primary)
  • Indications Glaucoma; Osteoarthritis; Plaque psoriasis; Rheumatoid arthritis; Uveitis
  • Focus Adverse reactions

    • Most Recent Events

    • 11 Aug 2017 New trial record
    • 07 Aug 2017 According to a Can-Fite BioPharma media release, in this study, piclidenoson doses were up to 3-fold higher than the highest dose expected to be used in the registration-directed clinical trials
    • 07 Aug 2017 According to a Can-Fite BioPharma media release, this trial is a regulatory safety requirement of both the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) prior to the initiation of Phase III studies.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top